Dr. Robert David Goldman, MD

Dr. Goldman practices at Orchard Creek Surgery Center - Mountain View in Mountain View, California.

Dr. Goldman's NPI, 1104989649, was assigned on December 18, 2006. Dr. Goldman graduated from Keck School of Medicine of USC in 1980. Dr. Goldman holds California license G44889.

Dr. Goldman's primary practice is Orchard Creek Surgery Center - Mountain View, at 525 South Drive, Suite 115, Mountain View, CA 94040. The practice phone is (650) 969-5600.

Dr. Goldman's primary practice is Orchard Creek Surgery Center - Mountain View in Mountain View, California. The medical group on file is Schweiger Dermatology Group, San Pedro.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldman practices. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Goldman's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Goldman is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Goldman's licenses on file in 2 states: California and Washington.

Dmand AI lists acute skin infection, contact dermatitis, scalp rash and skin discoloration among the conditions Dr. Goldman treats.

CMS data shows 259 Medicare services from Dr. Goldman across 9 procedure codes in 2024, for 127 Medicare patients. Medicare paid $15,884 for them. Every service was in an office.

CMS counts 127 Medicare patients who saw Dr. Goldman in 2024. The largest group is 75 to 84, with 53 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Goldman's median patient age at 59, with 50% women.

In 2024, Dr. Goldman wrote 257 Medicare Part D claims for 99 patients. 93% of them were for generic drugs. CMS names the drug for 185 of them, across 7 drugs with 11 or more claims each, at $8,292 in total drug cost. In 2023, CMS named 118 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Goldman for performance year 2024, reported as part of a group. Dr. Goldman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 52 procedures of removal of skin lesions by Dr. Goldman, more than 72% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 193 papers to Dr. Goldman, published from 2001 to 2019. 2009 was the busiest year, with 7. The most frequent topics are Intermediate Filaments, Cytoskeleton and Cell Line. Dr. Goldman has published most often in J Cell Biol. Dr. Goldman's most frequent co-authors are Luay M. Almassalha, MD, PhD, Brian Burke and Warner C. Greene, MD, PhD.

CMS Open Payments shows 22 general payments to Dr. Goldman from 11 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. UCB, Inc. paid the most, $156. It also lists 13 research payments totaling $2,134 in 2024, naming 1 clinical trial.

Dr. Goldman graduated from Keck School of Medicine of USC in 1980.

Dr. Goldman is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.